Minimal change disease (MCD) is one of the most common diseases leading to nephrotic syndrome in children and young adults. This pathology is characterized by the presence of edema, high proteinuria and hypoalbuminemia. At the same time, structural changes in the kidneys that could be seen with standard microscopy are absent, which determines the name of the disease. In essence, MCD is a consequence of the violation of the filtration function of the glomeruli of the kidneys, but the mechanisms of its occurrence and the factors predisposing to it have not been fully studied, which makes it a subject of active study in nephrology.
History of the disease and interesting historical facts
Minimal change disease was first described in 1957 by Dr. W. Schmidt, who noticed a connection between the absence of visible changes in the renal glomeruli and the manifestations of nephrotic syndrome in patients. Additional studies helped establish the role of this disease as one of the most common causes of nephrotic syndrome in children. In the 1970s, the concept emerged that minimal change disease may be a consequence of changes in immune mechanisms, including hypersensitivity reactions. Subsequent research has shown that this disease may be associated with viral infections, allergic reactions, and even certain drugs, opening up new perspectives in understanding the pathogenesis.
Epidemiology
According to epidemiological studies, minimal change disease accounts for approximately 80% cases of nephrotic syndrome in children and 10-15% in adults. It is most often diagnosed in children aged 2 to 6 years, making it one of the most common reasons for prescribing nephrotic syndrome therapy in pediatric practice. In the long term, most patients have a favorable outcome, but missed diagnostic moments can lead to the development of chronic kidney failure, which emphasizes the importance of early detection.
Genetic predisposition to this disease
Genetic predisposition to minimal change disease is a subject of scientific research. Studies of genes involved in the pathogenesis of the disease have shown that certain polymorphisms in genes responsible for the immune response, such as HLA-DRB1 and others, can increase the risk of developing MCD. There is evidence that genetic factors, such as mutations in genes encoding podocyte proteins, influence the development of this condition. However, this area remains poorly understood, and further research is needed to better understand the mechanism of genetic predisposition.
Risk factors for the development of this disease
The pathology in question is associated with several risk factors. These include:
- Viral infections, particularly hepatitis and HIV viruses, which can initiate an immune response
- Allergic reactions caused by both external and internal allergens
- Use of certain medications, such as nonsteroidal anti-inflammatory drugs and antibiotics
- The presence of concomitant autoimmune conditions such as systemic lupus erythematosus
Additionally, there is evidence that exposure to certain chemicals and toxins may also increase the risk of developing minimal change disease.
Diagnosis of this disease
Diagnosis of minimal change disease is based on the clinical picture and laboratory test results, including:
- Main symptoms: edema, proteinuria, hypoalbuminemia and arterial hypertension
- Laboratory tests: complete blood count, blood chemistry, urine analysis
- Radiological examinations: ultrasound examination of the kidneys, which allows to exclude other pathologies
- Other types of diagnostics: a kidney biopsy may be performed if the symptoms do not correspond to the typical course
- Differential diagnosis: It is necessary to exclude other causes of nephrotic syndrome, such as primary and secondary membranous glomerulonephritis
Each of these studies provides important information for adequate diagnosis and determination of treatment strategy.
Treatment
Treatment of minimal change disease can be divided into several stages: general treatment, pharmacological treatment and surgical intervention in rare cases. The main methods of therapeutic intervention include the following components:
- General treatment: limiting salt in the diet, monitoring blood pressure, following the regimen
- Pharmacological treatment: use of corticosteroids such as prednisolone to suppress the inflammatory process
- Surgical treatment: considered very rarely and only in cases of complicated disease
- Other treatments: Immunosuppressants such as cyclosporine or tacrolimus are used if there is resistance to corticosteroids
The need for such approaches largely depends on the individual patient's response to initial treatments and the presence of concomitant pathologies.
List of medications used to treat this disease
The following medications are used in the treatment of minimal change disease:
- Prednisolone
- Methylprednisolone
- Cyclosporine
- Tacrolimus
- Mercaptoproteinosil
- Aspirin (as antiplatelet therapy)
These drugs help reduce the activity of the inflammatory process and improve kidney function.
Disease monitoring
Monitoring minimal change disease involves regularly monitoring clinical symptoms and laboratory parameters. Important monitoring steps include:
- Regular urine tests to assess proteinuria levels
- Monitoring blood albumin levels to assess patient condition
- Regular blood pressure measurement
The prognosis for most patients with BMP is generally good, but underestimation of the disease can lead to complications outlined in the following sections.
Age-related features of the disease
In children, minimal change disease manifests itself as severe edema, increased proteinuria, and excessive water in the body, often without previous illnesses. In adults, the disease may be more latent, with a less pronounced clinical picture. In this regard, it is important to differentiate between minimal change disease and other diseases, such as diabetic nephropathy or primary glomerulonephritis.
Questions and Answers
- What are the main symptoms of minimal change disease? The main symptoms are edema, proteinuria, hypoalbuminemia and arterial hypertension.
- How is minimal change disease diagnosed? Diagnosis includes blood and urine tests, ultrasound examination of the kidneys and, in rare cases, kidney biopsy.
- What is the treatment for minimal change disease? Treatment includes corticosteroids, immunosuppressants, and supportive care.
- What is the likelihood of minimal change disease recurrence? Relapses may occur in 30-50% patients, especially if treatment is insufficient.
- How does minimal change disease affect a patient's life? With proper diagnosis and treatment, most patients recover, but long-term monitoring is required.
